Equities

Gan & Lee Pharmaceuticals

603087:SHH

Gan & Lee Pharmaceuticals

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)49.68
  • Today's Change-0.12 / -0.24%
  • Shares traded15.47m
  • 1 Year change+1.99%
  • Beta--
Data delayed at least 15 minutes, as of Nov 12 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 16-Nov-23
  • 15-Aug-24
  • 19-Sep-24
  • 17-Oct-24
  • 07-Nov-24
Select bar for recommendation details.
Recommendations07-Nov-24
Buy1
Outperform2
Hold1
Sell0
Strong Sell0

Share price forecast in CNY

The one analyst offering a 12 month price target expects Gan & Lee Pharmaceuticals share price to rise to 68.00 in the next year from the last price of 49.68.
High36.9%68.00
Med36.9%68.00
Low36.9%68.00

Dividends

In 2023, Gan & Lee Pharmaceuticals reported a dividend of 0.20 CNY. The 2 analysts covering the company expect dividends of 0.12 CNY for the upcoming fiscal year, a decrease of 42.50%.
Div growth (TTM)--
More ▼

Earnings history & estimates in CNY

On Oct 22, 2024, Gan & Lee Pharmaceuticals reported 3rd quarter 2024 earnings of 0.34 per share.
The next earnings announcement is expected on Mar 31, 2025.
Average growth rate+68.42%
Gan & Lee Pharmaceuticals reported annual 2023 earnings of 0.600 per share on Apr 24, 2024.
Average growth rate+11.99%
More ▼

Revenue history & estimates in CNY

Gan & Lee Pharmaceuticals had 3rd quarter 2024 revenues of 930.11m. This missed the 1.03bn estimate of the one analyst following the company. This was 33.63% above the prior year's 3rd quarter results.
Average growth rate+21.55%
Gan & Lee Pharmaceuticals had revenues for the full year 2023 of 2.61bn. This was 52.32% above the prior year's results.
Average growth rate+2.39%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.